open access

Vol 15, No 2 (2018)
Review paper
Get Citation

Duloxetine and venlafaxine ― SNRI the same or not?

Tomasz Tafliński
Psychiatria 2018;15(2):82-87.

open access

Vol 15, No 2 (2018)
Prace poglądowe - nadesłane

Abstract

The aim of the study is to compare pharmacological and clinical profiles of two leading on the Polish market drugs from the SNRI group ― duloxetine and venlafaxine. Duloxetine is indicated in Poland for the treatment of moderate to severe depressive episodes and pain associated with peripheral diabetic neuropathy in the dose range of 60 to 120 mg/day. Duloxetine may also be useful in the treatment of symptoms of generalized anxiety disorder. The effectiveness of duloxetine in treating pain symptoms accompanying depressive disorders increases the likelihood of achieving remission, which is still a challenge in modern psychiatry. Duloxetine can be effective in treating anergia and apathy due to specific affinity to brain dopaminergic system. In clinical practice, the pharmacokinetics of the drug and the need to adjust doses in smokers and in the case of other medicines and the presence of comorbidities should be considered. Compared to venlafaxine, duloxetine has less effect on the risk of increased blood pressure and less likelihood of withdrawal symptoms.

Abstract

The aim of the study is to compare pharmacological and clinical profiles of two leading on the Polish market drugs from the SNRI group ― duloxetine and venlafaxine. Duloxetine is indicated in Poland for the treatment of moderate to severe depressive episodes and pain associated with peripheral diabetic neuropathy in the dose range of 60 to 120 mg/day. Duloxetine may also be useful in the treatment of symptoms of generalized anxiety disorder. The effectiveness of duloxetine in treating pain symptoms accompanying depressive disorders increases the likelihood of achieving remission, which is still a challenge in modern psychiatry. Duloxetine can be effective in treating anergia and apathy due to specific affinity to brain dopaminergic system. In clinical practice, the pharmacokinetics of the drug and the need to adjust doses in smokers and in the case of other medicines and the presence of comorbidities should be considered. Compared to venlafaxine, duloxetine has less effect on the risk of increased blood pressure and less likelihood of withdrawal symptoms.

Get Citation

Keywords

SNRI, duloxetine, venlafaxine

About this article
Title

Duloxetine and venlafaxine ― SNRI the same or not?

Journal

Psychiatria (Psychiatry)

Issue

Vol 15, No 2 (2018)

Article type

Review paper

Pages

82-87

Bibliographic record

Psychiatria 2018;15(2):82-87.

Keywords

SNRI
duloxetine
venlafaxine

Authors

Tomasz Tafliński

References (17)
  1. Bieńkowski P. Właściwości farmakologiczne inhibitorów wychwytu zwrotnego serotoniny i noradrenaliny — przykład duloksetyny. Psychiatria 2017; 14. ; 2: 75–77.
  2. Maund E, Tendal B, Hróbjartsson A, et al. Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications. BMJ. 2014; 348: g3510.
  3. Dhillon S. Duloxetine: a review of its use in the management of major depressive disorder in older adults. Drugs Aging. 2013; 30(1): 59–79.
  4. Clinical Pharmacology . http://www.clinicalpharmacology.com Duloxetine..
  5. Richelson E. Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. J Clin Psychiatry. 2003; 64(Suppl 13): 5–150.
  6. Munro G. Dopamine D(1) and D(2) receptor agonism enhances antinociception mediated by the serotonin and noradrenaline reuptake inhibitor duloxetine in the rat formalin test. Eur J Pharmacol. 2007; 575(1-3): 66–74.
  7. Harada E, Kato M, Fujikoshi S, et al. Changes in energy during treatment of depression: an analysis of duloxetine in double-blind placebo-controlled trials. Int J Clin Pract. 2015; 69(10): 1139–1148.
  8. Smith T, Nicholson RA. Review of duloxetine in the management of diabetic peripheral neuropathic pain. Vasc Health Risk Manag. 2007; 3(6): 833–844.
  9. Murawiec S. Duloksetyna w leczeniu depresji z bólem fizycznym i psychicznym. Psychiatria . 2017; 14(3): 144–149.
  10. Ball SG, Desaiah D, Zhang Qi, et al. Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary. Drugs Context. 2013; 2013: 212245.
  11. Patejuk-Mazurek I. Wybrane leki przeciwdepresyjne i o działaniu przeciwlękowym — praktyczne wskazówki stosowania i opisy przypadków. Psychiatria . 2017; 14(3): 135–142.
  12. Cipriani A, Koesters M, Furukawa TA, et al. Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2012; 10: CD006533.
  13. Serafini G, Pompili M, Del Casale A, et al. Duloxetine versus venlafaxine in the treatment of unipolar and bipolar depression. Clin Ter. 2010; 161(4): 321–327.
  14. Arnold LM, Meyers AL, Sunderajan P, et al. The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder. Ann Clin Psychiatry. 2008; 20(4): 187–193.
  15. Nicolini H, Bakish D, Duenas H, et al. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial. Psychol Med. 2009; 39(2): 267–276.
  16. Perahia DGS, Pritchett YLu, Kajdasz DK, et al. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J Psychiatr Res. 2008; 42(1): 22–34.
  17. Citrome L. Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord. 2016; 196: 225–233.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl